Effectiveness and safety of once-weekly Semaglutide in patients with type 2 diabetes undergoing hemodialysis.

Effectiveness of once-weekly Semaglutide in patients with type 2 diabetes undergoing hemodialysis. - Effectiveness of once-weekly Semaglutide in patients with type 2 diabetes undergoing hemodialysis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047221

Enrollment

Registered

2022-03-20

Start date

2021-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes undergoing hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes undergoing hemodialysis in Sohbudai Nieren Clinic from September 2020 to March 2022.

Exclusion criteria

Exclusion criteria: Patients who refused to participate in this research.

Design outcomes

Primary

Measure	Time frame
Changes in glucose profiles before and after semaglutide administration	—

Secondary

Measure	Time frame
HbA1c, Glycated albumin, Interdialysis weight, Side effect	—

Countries

Japan

Contacts

Public ContactAkinori Hayashi

Kitasato University School of Medicine Endocrinology, Diabetes and Metabolism

ahayashi@kitasato-u.ac.jp0427788706

Outcome results